Rossari Biotech Ltd (ROSSARI) — shareholding pattern, promoter holding, financials and share price
About Rossari Biotech Ltd (ROSSARI)
Rossari Biotech Ltd operates in the Specialty Chemicals industry, within the Chemicals sector. It trades on the NSE as ROSSARI and on the BSE under scrip code 543213. Its ISIN is INE02A801020.
Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India. [1] Their 3 main product categories are [2] : - Home, personal care, and performance chemicals - Textile specialty chemical - Animal health and nutrition The company has two R&D facilities, one at Silvassa manufacturing facility and a research lab at IIT Bombay. [3]
Rossari Biotech Limited is a leading manufacturer of specialty chemicals, offering sustainable chemical solutions across various industries including HPPC, TSC, and AHN.
The company reported a 13% year-on-year revenue growth for Q3 FY26, driven by strong performance in international markets and steady growth across its core business segments.
Listed peers in Specialty Chemicals: Jubilant Agri & Consumer Products Ltd, Tatva Chintan Pharma Chem Ltd, DDev Plastiks Industries Ltd, NOCIL Ltd, Bhansali Engineering Polymers Ltd, Camlin Fine Sciences Ltd.
Valuation & Returns
10 Jul 2026At ₹526 a share on 10 Jul 2026, Rossari Biotech Ltd (ROSSARI) was valued at a price-to-earnings ratio of 19.53x against an industry P/E of 45.11x and a price-to-book of 2.19x on a book value of ₹240.71 per share as of Mar 2026. Solomo computes return on equity of 11.19% and return on capital employed of 13.06% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 19.53x
- Industry P/E
- 45.11x
- P/B
- 2.19x
- EPS (TTM)
- ₹26.94
- Book value / share
- ₹240.71
- ROE
- 11.19%
- ROCE
- 13.06%
- ROA
- 6.52%
- Debt / equity
- 0.33x
- Dividend yield
- 0.1%
- EBITDA margin
- 12.94%
- 52-week range
- ₹372.9 – ₹767.55
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Rossari Biotech Ltd (ROSSARI) reported revenue of ₹2,396 crore, net profit of ₹149 crore and earnings per share of ₹26.94. That compares with revenue of ₹2,080 crore and net profit of ₹136 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹685 crore and net profit ₹46 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,483 | 1,656 | 1,831 | 2,080 | 2,396 |
| Net profit (₹ cr) | 98 | 107 | 131 | 136 | 149 |
| EPS (₹) | 17.74 | 19.45 | 23.66 | 24.63 | 26.94 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 20.47% | 21.57% | 15.19% |
| Profit growth | 12.55% | 26.01% | 9.41% |
| Stock price CAGR | -14% | -15% | -26% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 68.14% of Rossari Biotech Ltd (ROSSARI) (down 0.01 pp QoQ), foreign institutional investors (FII) hold 2.02% and domestic institutional investors (DII) hold 14.64%. Market capitalisation was ₹2,914 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2020.
Largest disclosed public shareholders in Jun 2026: Uti-Flexi Cap Fund 6.36%, Life Insurance Corporation Of India 4.01%, Canara Robeco Mutual Fund A/C Canara Robeco Small Cap Fund 1.9%, Motilal Oswal Small Cap Fund 1.42%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 68.14% | - | 2.02% | 14.64% | 31.86% |
| Mar 2026 | 68.15% | - | 2.18% | 18.2% | 31.85% |
| Dec 2025 | 68.16% | - | 2.33% | 18.26% | 31.84% |
| Sep 2025 | 68.17% | - | 2.69% | 18.18% | 31.83% |
| Jun 2025 | 68.17% | - | 3.48% | 17.84% | 31.83% |
| Mar 2025 | 68.18% | - | 3.98% | 17.59% | 31.82% |
| Dec 2024 | 68.19% | - | 3.74% | 17.47% | 31.81% |
| Sep 2024 | 68.27% | - | 3.74% | 17.34% | 31.73% |